Definition
Visceral adipose tissue is referenced in the context of Tesamorelin, which is FDA-approved for its reduction in HIV-associated lipodystrophy. Phase III clinical trials demonstrated significant reduction in visceral adipose tissue (VAT) with Tesamorelin administration, along with improvements in lipid profiles. VAT reduction is distinct from subcutaneous fat reduction and is clinically significant for metabolic health.
Source: Tesamorelin peptide summary and FAQ